differences between rowatinex and proximol and the best for kidney stones

differences between rowatinex and proximol and the best for kidney stones and treating renal colic, they are effective medications for eliminating kidney stones and urinary tract stones. They help treat excess fluid, thus improving urine flow and reducing kidney pain. This is due to their active ingredients that cleanse the urinary tract and urethra, and treat infections of the reproductive system and ureter. We will explain the difference between each of them, their mechanism of action, and the recommended dosages in this article.

Rowatinex Ingredients

It consists of the following active ingredients:

• Beta-pinene.
• Alpha-pinene.
• Olive oil.
• Camphene.
• Finchon.
• Cineole.
• Borneol.

Proximol Ingredients

It contains the following active ingredients:

• Hexamine, a urinary tract antiseptic that helps eliminate bacteria that cause infection.
• Halfa bark, a natural herb used to treat kidney and ureter stones and urinary tract infections.
• Piperazine is a substance that prevents the deposition of salts and the formation of stones in the kidneys.

Author Name: Pharmacist Nada Mohamed Mostafa

Scientific Degree: pharmacist

Country: Egypt

Clinical Pharmacist | Medical & Pharmaceutical Content Writer & Reviewer

A licensed Egyptian pharmacist registered with the Egyptian Pharmacists Syndicate, holding a Bachelor of Pharmaceutical Sciences (B.Pharm.) from the Faculty of Pharmacy, Cairo University in Pharmaceutical Chemistry. She possesses extensive hands-on experience in community pharmacy practice and clinical patient education, specializing in pharmacokinetics, drug-drug interactions, and evidence-based dosing guidelines for both adults and pediatrics.

Dr. Nada serves as a medical writer and reviewer at Rosheta, dedicated to simplifying complex pharmacological data for patients while delivering accurate, up-to-date clinical insights rooted in approved prescribing information and official regulatory standards, including the Egyptian Drug Authority (EDA) and the U.S. FDA.

Published Date: 12 August 2025